Hoffmann-la Roche Inc.

Roche Glycart Ag

F. Hoffmann-la Roche Ag

Joerg Moelleken

Guy Georges

Hubert Kettenberger

Stefan Dengl

Michael Molhoj

Olaf Mundigl

Jens Fischer

Ekkehard Moessner

Tilman Schlothauer

Christian Gassner

Stefan Seeber

Guido Hartmann

Peter Michael Huelsmann

Ulrich Goepfert

Jens Niewoehner

Fiona Grueninger

Thomas Emrich

Joerg Thomas Regula

Sabine Imhof-Jung

Georg Tiefenthaler

Roland Beckmann

Sebastian Fenn

Maximiliane Koenig

Christian Klein

Pablo Umana

Ralf Hosse

Georg Fertig

Peter Bruenker

Klaus Kaluza

Claudia Ferrara Koller

Sandra Grau-Richards

Kristian Hobolt Jensen

Joerg Benz

Huisheng Wang

Valeria Lifke

Inja Waldhauer

Kathryn Elizabeth Packman

Johannes Auer

Sonja Offner

Achal Mukundrao Pashine

Martin Bader

Gregor Jordan

Ralf Schumacher

Stefan Klostermann

Christian Schantz

Sabine Hoves

Apollon Papadimitriou

Anton Jochner

Barbara Weiser

Stefan Lorenz

Kevin Brady

Adrian Hugenmatter

Valeria Runza

Meher Majety

Shu Feng

Sabine Gruener

Huifeng Niu

Martin Schaefer

Sebastian Breuer

Ningping Feng

Manuel Endesfelder

Runyi Adeline Lam

Michael Gertz

Marc Bedoucha

Wei Shiong Adrian Ho

Siok Wan Gan

Maria Viert

Sherif Daouti

Alexander Bujotzek

Francesca Ros

Joerg-Thomas Regula

Esther Koenigsberger

Claudia Kirstenpfad

Andreas Hinz

Janina Speck

Felix Bormann

Florian Lipsmeier

Christoph Ullmer

Kristian Hobolt-Jensen

Achal Pashine

Thomas Joerg Regula

Alexander Haas

Daniela Matscheko

Wolfgang Meschendoerfer

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

Humanized anti-Tau(PS422) antibodies and methods of use

Herein is reported a method for determining the binding affinity of the binding sites of a bivalent full length antibody of the human IgG1 subclass to a homo-multimeric antigen comprising the steps of i) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain ofat a pH of from pH 7.5 to pH 8.5, in the presence of a reducing agent, at a temperature of from 30° C. to 42° C., for time of from 10 min. to 240 min. to cleave the antibody into Fabs and Fc-region, and ii) determining the binding affinity of the Fabs of the antibody for its antigen using a surface plasmon resonance method by directly applying the incubated reaction mixture obtained in the previous step in the surface plasmon resonance method and therewith determining the binding affinity of the binding sites of the bivalent full length antibody of the human IgG1 subclass.

Direct affinity measurement of human IgG1 binding multimeric antigens

The present invention relates to anti-HLA-G antibodies and methods of using the same.

Anti-HLA-G antibodies and methods of use thereof

The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Bispecific anti-CCL2 antibodies

Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain ofunder conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.

Method for determining the in vivo interaction mode

The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.

Antibody that binds to VEGF and IL-1beta and methods of use

The present invention relates to anti-VEGF antibodies and methods of their production and their use.

Anti-VEGF antibodies and methods of use

The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.

Antibody that binds to VEGF-A and ANG2 and methods of use

Humanized anti-Tau(pS422) antibodies and methods of use

The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Antibodies specific for DR5 and methods of use

Humanized anti-tau(pS422) antibodies and methods of use

Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.

Bispecific antibodies and methods of use in ophthalmology

Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.

Anti-ANG2 antibodies and methods of use

Growing community of inventors

Munich, Germany

Joerg Moelleken